License cancellation trial on liquid-type Uwangchungsimwon is in favor of Chosun Pharm

Published: 2002-07-11 06:58:00

Updated: 2002-07-11 06:58:00

The Seoul High Court ruled that the administrative disposition of the Korea Food and Drug Administration (KFDA) on Chosun's Uwangchungsimwon is deemed unfair, in a recent lawsuit raised by Chosun Pharm against the license cancellation of its Uwangchungsimwon in liquid form imposed by the KFDA, cl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK